Information Provided By: 
Fly News Breaks for July 13, 2016
RIGL
Jul 13, 2016 | 07:08 EDT
H.C. Wainwright analyst Shaunak Deepak started Rigel Pharmaceuticals with a Buy rating and $6 price target. "We would be buyers of Rigel going into the August readout from the first Phase 3 trial for its Syk inhibitor fostamatib in ITP based on compelling data from a Phase 2 trial," Deepak tells investors in a research note.
News For RIGL From the Last 2 Days
There are no results for your query RIGL
